JPRN-jRCTs031220542招募中2 期
Fecal microbiota transplantation in combination with antibiotics for patients with active ulcerative colitis
agahara Akihito0 个研究点目标入组 37 人开始时间: 2023年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion criteria for patients
- •1) Patients with active left-sided ulcerative colitis or pancolitis.
- •2) Inadequate response or intolerance to 5-ASA.
- •3) Patients with a mean stool frequency MMDAI subscore of 0-2 in the last 3 days prior to the date of eligibility confirmation
- •4) Patients with a mean blood stool MMDAI subscore of 1-2 and a subscore of 1 point or higher in the last 3 days prior to the date of eligibility confirmation
- •5) Patients with MMDAI endoscopic subscore of 2 points evaluated by colonoscopy performed between 2 weeks prior to the eligibility confirmation date and the eligibility confirmation date
- •6) Patients diagnosed with ulcerative colitis for more than 12 weeks prior to the eligibility confirmation date
- •7) Age 16 years or older at the time of obtaining informed consent
- •8) Outpatients / Inpatients: Outpatients only
- •9) Patients who can obtain written consent of the research participation by free will. If the patient is under 18 years of age at the time of consent, he/she must be able to obtain a written consent from his/her legal guardian or representative.
- •Inclusion criteria for donors
- •1) Healthy persons who are 18 years of age or older at the time of obtaining consent.
- •2) Persons who can donate stool regularly.
- •3) Persons who can undergo a medical interview and screening tests (blood test, stool test, and saliva test) on a regular basis
- •4) Persons who have the capacity to consent and can obtain written consent of their own free will.
排除标准
- •Exclusion criteria for patients
- •1) Patients with severe allergies to the drugs used in this study
- •2) Patients who have received any of the following medications or procedures within the time period specified below
- •(1) 5-ASA preparations in excess of the prescribed dose : 4 weeks prior to the date of eligibility confirmation
- •(2) Steroids (oral, rectal, suppository, hemorrhoid treatment, inhalation, injection): 4 weeks prior to the date of eligibility confirmation
- •(3) Cytapheresis: 4 weeks prior to date of eligibility confirmation
- •(4) Immunomodulators (cyclosporine, tacrolimus, methotrexate, azathioprine, 6-mercaptopurine): 4 weeks prior to the date of eligibility confirmation
- •(5) Biologics: 12 weeks prior to the date of eligibility confirmation
- •(6) Antibiotics for the treatment of ulcerative colitis: 3 months prior to the date of eligibility confirmation
- •(7) Antidiarrheal drugs: 2 weeks prior to the date of eligibility confirmation
- •(8) Antidiarrheal treatment for IBS-D: 2 weeks prior to the date of eligibility confirmation
- •(9) Intestinal cleansing agents (except for use as a pretreatment for colonoscopy for this study): 2 weeks prior to the date of eligibility confirmation
- •(10) Laxatives (except for use in the pretreatment of colonoscopy for this study): 2 weeks prior to the date of eligibility confirmation
- •(11) Enema (except for use as a pre-treatment for colonoscopy for this study): 2 weeks prior to the date of eligibility confirmation
- •(12) Live vaccines: 4 weeks prior to the date of eligibility confirmation
- •(13) Probiotics: 1 week prior to the date of eligibility confirmation
- •3) Patients who have changed the dosage of the following drug therapies within the time period indicated below (if the route of administration is the same, a change in drug form is acceptable)
- •(1) 5-ASA (oral): 4 weeks prior to the date of eligibility confirmation
- •4) Patients with a history of colorectal resection or patients scheduled for surgical treatment of the gastrointestinal tract during the study period
- •5) Patients who are clinically suspected of having infectious enteritis
- •6) Patients with tuberculous disease
- •7) Patients with liver cirrhosis (e.g., end-stage primary biliary cirrhosis) with signs of portal hypertension
- •8) Patients with infections and deep-seated fungal infections for which there are no effective antimicrobial agents
- •9) Patients with severe cardiac disease
- •10) Patients with renal impairment (serum creatinine of 2.0 mg/dL or higher, or BUN of 25 mg/dL or higher)
- •11) Patients with hepatic impairment (total bilirubin of 3.0 mg/dL or higher, or AST (GOT) or ALT (GPT)* of 100 IU/L or higher)
- •12) Patients with malignant tumors or patients who have not been treated for 5 years
- •13) Patients with obvious psychiatric symptoms (equivalent to Grade 2 or higher in Criteria for Classification of Severity of Adverse Reactions to Drugs (June 29, 1992, Drug Proposal No. 80), regardless of treatment)
- •14) Patients with a history of drug addict or alcohol addiction
- •15) Pregnant women, lactating women, women who may be pregnant, women who wish to become pregnant from the time of obtaining consent through the duration of treatment, and women who cannot agree to use an appropriate method of contraception (intrauterine devices, pessaries, or compliance with partner condom use; however, oral contraceptives are prohibited)
- •16) Patients who are participating in other clinical studies or trials, including follow-up studies, at the time of obtaining consent
研究者
相似试验
进行中（未招募）
Unknown
Role of transplantation of fecal microbiota from healthy individuals to patients with Crohn's disease and its effect on achieving control of disease activityCrohn's disease of both small and large intestineDigestive SystemISRCTN15318304Dayanand Medical College & Hospital36
招募中
2 期
Fecal microbiota transplantation for intractable gastrointestinal diseases(FEMIGI study)1)Clostridium difficile infection 2)Crohn disease, ulcerative colitis 3)Chronic Enteropathy associatJPRN-jRCTs041190021Ohmiya Naoki50
尚未招募
不适用
Fecal microbiota transplantation for eradication of Vancomycin-Resistant EnterococciVancomycin-resistant Enterococci carriageAntibiotic resistanceDragerschap vancomycine-resistente Enterococ Antibiotica resistentieNL-OMON25381niversity Medical Center Utrecht10
撤回
2 期
Fecal Microbiota Transplantation for eradication of Vancomycin-resistant Enterococci (FAVOR): a pilot studyCarriage of vancomycin-resistant Enterococvancomycin-resistant Enterococ carrier10004018NL-OMON46675niversitair Medisch Centrum Utrecht10
已完成
不适用
A trial of fecal microbiota transplantation and / or antibiotics therapy for ulcerative colitisulcerative colitisJPRN-UMIN000018642Juntendo university school of medicine Department of gastroenterology50